Hangzhou Coco Healthcare Products Co.,Ltd. (SHE:301009)
China · Delayed Price · Currency is CNY 13.41
+0.02 (0.15%)
At close: Feb 6, 2026
SHE:301009 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,099 | 1,058 | 1,054 | 1,166 | 1,170 | 1,622 |
Other Revenue | 20.28 | 20.28 | 27.55 | 20.24 | 16.19 | 13.55 |
| 1,119 | 1,079 | 1,081 | 1,186 | 1,186 | 1,635 | |
Revenue Growth (YoY) | 5.18% | -0.27% | -8.83% | -0.01% | -27.44% | 39.31% |
Cost of Revenue | 882.08 | 866.7 | 900.27 | 1,043 | 973.16 | 1,182 |
Gross Profit | 236.84 | 211.84 | 181.22 | 143.63 | 213.25 | 452.95 |
Selling, General & Admin | 181.9 | 165.35 | 135.44 | 125.51 | 127.85 | 90.34 |
Research & Development | 47.31 | 45.04 | 44.11 | 50.98 | 49.27 | 58.84 |
Other Operating Expenses | -2.62 | -5.14 | -4.38 | 3.13 | 4.26 | 3.12 |
Operating Expenses | 224.98 | 206.08 | 171.69 | 184.84 | 179.32 | 154.18 |
Operating Income | 11.87 | 5.76 | 9.53 | -41.21 | 33.92 | 298.78 |
Interest Expense | -1.76 | -0.73 | -0.65 | -0.28 | -0.96 | -2.14 |
Interest & Investment Income | 27.71 | 20.72 | 24.25 | 23.58 | 17.7 | 3.46 |
Currency Exchange Gain (Loss) | 8.72 | 8.72 | 5.66 | 16.54 | -4.37 | -21.38 |
Other Non Operating Income (Expenses) | -8.88 | -3.18 | -1.56 | -1.22 | -5.63 | -4.25 |
EBT Excluding Unusual Items | 37.66 | 31.29 | 37.23 | -2.59 | 40.66 | 274.47 |
Gain (Loss) on Sale of Investments | 0.73 | -0.38 | -3.34 | - | - | - |
Gain (Loss) on Sale of Assets | -0.09 | -0.04 | -0.1 | 0.12 | 0.04 | -0.01 |
Asset Writedown | -1.47 | -0.21 | -14.09 | -62.3 | -0.16 | -32.59 |
Other Unusual Items | 2.23 | 2.23 | -0.24 | 8.39 | 2.99 | 12.43 |
Pretax Income | 39.05 | 32.91 | 19.45 | -56.37 | 43.53 | 254.3 |
Income Tax Expense | 2.23 | 2.34 | 1.69 | -0.13 | 4.09 | 31.2 |
Earnings From Continuing Operations | 36.82 | 30.57 | 17.76 | -56.25 | 39.44 | 223.1 |
Minority Interest in Earnings | 0.26 | 0.61 | 2.42 | 13.12 | 0.31 | -9.09 |
Net Income | 37.09 | 31.17 | 20.18 | -43.13 | 39.75 | 214.01 |
Net Income to Common | 37.09 | 31.17 | 20.18 | -43.13 | 39.75 | 214.01 |
Net Income Growth | 146.38% | 54.44% | - | - | -81.43% | 144.72% |
Shares Outstanding (Basic) | 258 | 260 | 288 | 270 | 234 | 204 |
Shares Outstanding (Diluted) | 258 | 260 | 288 | 270 | 234 | 204 |
Shares Change (YoY) | -10.15% | -9.91% | 6.98% | 15.29% | 14.71% | 1.96% |
EPS (Basic) | 0.14 | 0.12 | 0.07 | -0.16 | 0.17 | 1.05 |
EPS (Diluted) | 0.14 | 0.12 | 0.07 | -0.16 | 0.17 | 1.05 |
EPS Growth | 174.22% | 71.43% | - | - | -83.81% | 140.01% |
Free Cash Flow | 63.42 | -22.91 | 161.69 | -153.6 | -189.92 | 175.15 |
Free Cash Flow Per Share | 0.25 | -0.09 | 0.56 | -0.57 | -0.81 | 0.86 |
Dividend Per Share | 0.070 | 0.070 | 0.075 | - | 0.070 | - |
Dividend Growth | -6.67% | -6.67% | - | - | - | - |
Gross Margin | 21.17% | 19.64% | 16.76% | 12.11% | 17.97% | 27.70% |
Operating Margin | 1.06% | 0.53% | 0.88% | -3.47% | 2.86% | 18.27% |
Profit Margin | 3.31% | 2.89% | 1.87% | -3.64% | 3.35% | 13.09% |
Free Cash Flow Margin | 5.67% | -2.12% | 14.95% | -12.95% | -16.01% | 10.71% |
EBITDA | 66.9 | 60.23 | 63.25 | 18.53 | 82.5 | 338.02 |
EBITDA Margin | 5.98% | 5.58% | 5.85% | 1.56% | 6.95% | 20.67% |
D&A For EBITDA | 55.04 | 54.47 | 53.72 | 59.74 | 48.57 | 39.24 |
EBIT | 11.87 | 5.76 | 9.53 | -41.21 | 33.92 | 298.78 |
EBIT Margin | 1.06% | 0.53% | 0.88% | -3.47% | 2.86% | 18.27% |
Effective Tax Rate | 5.71% | 7.11% | 8.69% | - | 9.40% | 12.27% |
Revenue as Reported | 1,119 | 1,079 | 1,081 | 1,186 | 1,186 | 1,635 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.